1 insider bought shares over the last 90 days, the latest by Chen Yanling, filed 04 Sept 2026.
Sihuan Pharmaceutical Holdings Group Ltd. is a Health Care company. Its directors and officers file their transactions with HKEX. The last twelve months, up to 25 October 2026, brought 5 filings signed by 5 insiders.
Every open-market trade in the period is a purchase: 4 purchases, from 4 insiders, and not a single sale. The amount is not disclosed for 4 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Those buying include 4 senior executives.
For context, the typical company on the same exchange (median of 1,315 companies) published 4 filings over the same period, against 5 filings here. Looking back to 2017, when coverage begins, insiders filed 22 purchases and 18 sales.
The latest purchase dates back some time: it was published 51 days ago, on 4 September 2026. Typically, a trade is published a median of 6 days after it takes place. Until a filing is published, the market cannot know about the trade.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 91 declarations
Sihuan Pharmaceutical Holdings Group Ltd. is a China-based pharmaceutical company engaged in the development, manufacturing, and marketing of drugs. It primarily focuses on pharmaceutical products for the central nervous system and cardiovascular diseases.
Purchases our model currently ranks for the recommendations list.
All recommendations